vs

Side-by-side financial comparison of ARGAN INC (AGX) and Bio-Techne (TECH). Click either name above to swap in a different company.

Bio-Techne is the larger business by last-quarter revenue ($311.4M vs $251.2M, roughly 1.2× ARGAN INC). Bio-Techne runs the higher net margin — 16.4% vs 12.2%, a 4.2% gap on every dollar of revenue. On growth, Bio-Techne posted the faster year-over-year revenue change (-1.5% vs -2.3%). Over the past eight quarters, ARGAN INC's revenue compounded faster (23.5% CAGR vs 1.3%).

Argan Inc. is a diversified holding company that provides comprehensive engineering, construction, project management and consulting services. Its core operating segments focus on power generation, telecommunications, industrial infrastructure and renewable energy projects, primarily serving public and private sector clients across North America.

Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.

AGX vs TECH — Head-to-Head

Bigger by revenue
TECH
TECH
1.2× larger
TECH
$311.4M
$251.2M
AGX
Growing faster (revenue YoY)
TECH
TECH
+0.8% gap
TECH
-1.5%
-2.3%
AGX
Higher net margin
TECH
TECH
4.2% more per $
TECH
16.4%
12.2%
AGX
Faster 2-yr revenue CAGR
AGX
AGX
Annualised
AGX
23.5%
1.3%
TECH

Income Statement — Q3 FY2026 vs Q3 FY2026

Metric
AGX
AGX
TECH
TECH
Revenue
$251.2M
$311.4M
Net Profit
$30.7M
$51.0M
Gross Margin
18.7%
66.9%
Operating Margin
13.0%
24.2%
Net Margin
12.2%
16.4%
Revenue YoY
-2.3%
-1.5%
Net Profit YoY
9.7%
126.0%
EPS (diluted)
$2.17
$0.32

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AGX
AGX
TECH
TECH
Q1 26
$311.4M
Q4 25
$251.2M
$295.9M
Q3 25
$237.7M
Q2 25
$193.7M
$317.0M
Q1 25
$232.5M
$316.2M
Q4 24
$257.0M
$297.0M
Q3 24
$227.0M
$289.5M
Q2 24
$157.7M
$306.1M
Net Profit
AGX
AGX
TECH
TECH
Q1 26
$51.0M
Q4 25
$30.7M
$38.0M
Q3 25
$35.3M
Q2 25
$22.6M
$-17.7M
Q1 25
$31.4M
$22.6M
Q4 24
$28.0M
$34.9M
Q3 24
$18.2M
$33.6M
Q2 24
$7.9M
$40.6M
Gross Margin
AGX
AGX
TECH
TECH
Q1 26
66.9%
Q4 25
18.7%
64.6%
Q3 25
18.6%
Q2 25
19.0%
62.7%
Q1 25
20.5%
67.9%
Q4 24
17.2%
65.3%
Q3 24
13.7%
63.2%
Q2 24
11.4%
66.4%
Operating Margin
AGX
AGX
TECH
TECH
Q1 26
24.2%
Q4 25
13.0%
18.4%
Q3 25
12.6%
Q2 25
12.6%
-7.5%
Q1 25
14.1%
12.2%
Q4 24
11.8%
16.0%
Q3 24
8.2%
13.8%
Q2 24
4.1%
15.0%
Net Margin
AGX
AGX
TECH
TECH
Q1 26
16.4%
Q4 25
12.2%
12.8%
Q3 25
14.8%
Q2 25
11.6%
-5.6%
Q1 25
13.5%
7.1%
Q4 24
10.9%
11.7%
Q3 24
8.0%
11.6%
Q2 24
5.0%
13.3%
EPS (diluted)
AGX
AGX
TECH
TECH
Q1 26
$0.32
Q4 25
$2.17
$0.24
Q3 25
$2.50
Q2 25
$1.60
$-0.11
Q1 25
$2.26
$0.14
Q4 24
$2.00
$0.22
Q3 24
$1.31
$0.21
Q2 24
$0.58
$0.26

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AGX
AGX
TECH
TECH
Cash + ST InvestmentsLiquidity on hand
$423.7M
$209.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$419.7M
$2.1B
Total Assets
$1.1B
$2.6B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AGX
AGX
TECH
TECH
Q1 26
$209.8M
Q4 25
$423.7M
$172.9M
Q3 25
$275.5M
Q2 25
$304.3M
$162.2M
Q1 25
$298.4M
$140.7M
Q4 24
$299.8M
$177.5M
Q3 24
$302.0M
$187.5M
Q2 24
$291.8M
$152.9M
Total Debt
AGX
AGX
TECH
TECH
Q1 26
Q4 25
$260.0M
Q3 25
Q2 25
$346.0M
Q1 25
$330.0M
Q4 24
$300.0M
Q3 24
$300.0M
Q2 24
$319.0M
Stockholders' Equity
AGX
AGX
TECH
TECH
Q1 26
$2.1B
Q4 25
$419.7M
$2.0B
Q3 25
$393.2M
Q2 25
$363.9M
$1.9B
Q1 25
$351.9M
$2.0B
Q4 24
$328.7M
$2.1B
Q3 24
$308.1M
$2.1B
Q2 24
$293.2M
$2.1B
Total Assets
AGX
AGX
TECH
TECH
Q1 26
$2.6B
Q4 25
$1.1B
$2.5B
Q3 25
$882.7M
Q2 25
$792.2M
$2.6B
Q1 25
$836.2M
$2.6B
Q4 24
$768.9M
$2.7B
Q3 24
$726.6M
$2.7B
Q2 24
$624.4M
$2.7B
Debt / Equity
AGX
AGX
TECH
TECH
Q1 26
Q4 25
0.13×
Q3 25
Q2 25
0.18×
Q1 25
0.16×
Q4 24
0.14×
Q3 24
0.14×
Q2 24
0.15×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AGX
AGX
TECH
TECH
Operating Cash FlowLast quarter
$172.5M
Free Cash FlowOCF − Capex
$171.9M
FCF MarginFCF / Revenue
68.4%
Capex IntensityCapex / Revenue
0.2%
Cash ConversionOCF / Net Profit
5.61×
TTM Free Cash FlowTrailing 4 quarters
$283.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AGX
AGX
TECH
TECH
Q1 26
Q4 25
$172.5M
Q3 25
$34.6M
Q2 25
$35.3M
$98.2M
Q1 25
$44.6M
$41.1M
Q4 24
$31.8M
$84.3M
Q3 24
$73.5M
$63.9M
Q2 24
$17.7M
$75.5M
Free Cash Flow
AGX
AGX
TECH
TECH
Q1 26
Q4 25
$171.9M
Q3 25
$32.9M
Q2 25
$34.9M
$93.3M
Q1 25
$43.3M
$31.0M
Q4 24
$29.2M
$77.5M
Q3 24
$71.1M
$54.7M
Q2 24
$17.4M
$57.5M
FCF Margin
AGX
AGX
TECH
TECH
Q1 26
Q4 25
68.4%
Q3 25
13.8%
Q2 25
18.0%
29.4%
Q1 25
18.6%
9.8%
Q4 24
11.4%
26.1%
Q3 24
31.3%
18.9%
Q2 24
11.0%
18.8%
Capex Intensity
AGX
AGX
TECH
TECH
Q1 26
Q4 25
0.2%
Q3 25
0.7%
Q2 25
0.2%
1.5%
Q1 25
0.6%
3.2%
Q4 24
1.0%
2.3%
Q3 24
1.0%
3.2%
Q2 24
0.2%
5.9%
Cash Conversion
AGX
AGX
TECH
TECH
Q1 26
Q4 25
5.61×
Q3 25
0.98×
Q2 25
1.57×
Q1 25
1.42×
1.82×
Q4 24
1.13×
2.42×
Q3 24
4.04×
1.90×
Q2 24
2.24×
1.86×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AGX
AGX

Power Industry Services$195.5M78%
Industrial Construction Services$49.4M20%
Telecommunications Infrastructure Services$6.3M3%

TECH
TECH

Protein Sciences segment revenue$226.2M73%
Diagnostics and Spatial Biology segment revenue$85.6M27%
Other revenue (1)$5.4M2%

Related Comparisons